cbdMD (YCBD) Registration Filing summary

Company overview and business model

• Operates nationally recognized CBD brands, including cbdMD, Paw CBD, Bluebird Botanicals, ATRx Labs, and Herbal Oasis, offering a range of hemp-derived and functional mushroom products.

• Products are distributed via e-commerce, third-party sites, select distributors, marketing partners, and brick-and-mortar retailers.

• Focuses on product innovation, clinical claims, and quality, with ongoing investments in R&D through cbdMD Therapeutics.

• Recent acquisition of Bluebird Botanicals aims to expand customer base and product offerings, with expected revenue growth and SG&A savings.

Financial performance and metrics

• Bluebird Botanicals acquisition expected to add approximately $600,000 in quarterly revenue, with potential for further growth and positive impact on EBITDA and net income.

• Management is focused on achieving positive earnings through portfolio optimization, cost controls, and targeted marketing investments.

Use of proceeds and capital allocation

• $2,250,000 raised from Series C Preferred Stock private placement, with proceeds allocated to working capital and general corporate purposes.

• No proceeds from the resale of shares by selling shareholders; all such proceeds go to the selling shareholders.